Background: Regulatory B cells (Bregs), which protect from autoimmunity, are deficient in multiple sclerosis (MS). Novel regulatory B cell subsets CD19 + CD24 hi CD38 hi cells and CD19 + PD-L1 hi cells, with disparate regulatory mechanisms have been defined. Alemtuzumab provides a long-lasting suppression of disease activity in MS. In contrast to its documented efficacy, alemtuzumab's mechanism of action is not fully understood and information about the composition of repopulating B cell pool is scarce. Aim: To characterize repopulated B cell subsets and elucidate alemtuzumab's mechanism of action in B cell perspective. Methods: The frequency and the absolute number of Bregs were studied in peripheral blood mononuclear cells (PBMC) of 37 MS patients and 11 healthy controls (HC). Longitudinal analysis of the frequency and the absolute number of Bregs in PBMC of 11 MS patients was evaluated, before and at 6, 9, and 12 months post alemtuzumab. Results: We found deficiency of CD19
+

CD24
hi CD38 hi cells during relapse compared to remission and HC (relapse vs remission: p = 0.0006, relapse vs HC: p = 0.0004). CD19 + PD-L1 hi cells were deficient during relapse than remission and HC (relapse vs remission: p = 0.0113, relapse vs HC: p = 0.0007). Following alemtuzumab, the distribution of B cells shifts towards naïve phenotype and Breg deficiency is restored. The frequency of CD19 +
hi CD38 hi cells was significantly increased at 6 M and 9 M compared to 0 M (6 M vs 0 M: p = 0.0004, 9 M vs 0 M: p = 0.0079). At 9 M, the frequency of CD19 + CD24 hi CD38 hi cells started to decrease and by 12 M the frequency was reduced compared to 6 M, although it was significantly higher than baseline level (12 M 
Background
The concept that multiple sclerosis (MS) is a T-cell-mediated disease has been changed and it is now widely accepted that B cells play a part in the pathogenesis of MS. [1] [2] [3] Multiple roles of B cells have been elucidated emphasizing that B cells have dual contribution to autoimmunity [1, [4] [5] [6] . Hence, the concept of regulatory B cells (Breg) has emerged, proving that B cell subset distribution is far more complex than the original concept. A novel Breg subset that was originally known as immature transitional B cells (CD19   +   CD24 hi CD38 hi ) has been described to have regulatory capacity through interleukin-10 production [7] . Another study has found B cells highly expressing programmed death ligand-1 (CD19 + PD-L1 hi cells) that exert regulatory function through cell-to-cell contact via interaction of CD19 + PD-L1
hi cells with PD-1 on T cells, resulting in suppression of T follicular helper (Tfh) cell differentiation and expansion, which are the cell type known to be involved in the relapse of MS patients [8, 9] .
Alemtuzumab is a highly effective treatment in relapsing MS. It provides a long-lasting suppression of disease activity by altering the proportion of lymphocyte subsets with preferential increase of regulatory T cells (Treg) [10, 11] . In contrast to alemtuzumab's documented efficacy, alemtuzumab's mechanism of action is not fully understood and information about the composition of the repopulating B cell pool, especially Breg, is scarce.
Here 
Methods
Study population
For cross-sectional study, 20 MS patients during relapse (MS-relapse) and 17 MS patients in remission (MS-remission) and 11 healthy controls (HC) were included. For longitudinal analysis, 11 patients who were treated with alemtuzumab were included. All MS patients fulfilled the 2010 McDonald's criteria [12] . Current study was approved by the Institutional Review Board, and informed consent was obtained from each subject. Demographic and clinical characteristics of participants are summarized in Table 1 .
Flow cytometry
For cross-sectional study, fresh peripheral blood mononuclear cells (PBMCs) were surface stained with monoclonal antibodies against CD19-APC-cy7, CD27-FITC, CD24-BV421, CD38-BV510, and PD-L1(CD274)-PE-cy7 (BD Biosciences). For longitudinal study, frozen PBMCs, collected from 11 RRMS patients undergoing alemtuzumab at baseline and 6, 9, and 12 months, were surface stained with monoclonal antibodies as stated above.
Statistical analysis
We performed analysis of significance in Prism (GraphPad, La Jolla, USA (Fig. 1c) . Although no significant difference was observed, the absolute number of CD19 + PD-L1 hi cells was reduced in MS-relapse compared to MS-remission (Fig. 2c ).
Preferential reconstitution of naïve B cells following alemtuzumab
As expected, the frequency and absolute number of total lymphocytes was decreased at 6 months and gradually increased up to 12 months post alemtuzumab (Fig. 3a) . The frequency and the absolute number of memory B cells and plasmablasts were significantly decreased compared to pre-treatment level, and naïve B cells comprised the majority of repopulated CD19 + B cells (Fig. 3b) . 
Breg deficiency in MS is restored following alemtuzumab
The frequency and the absolute number of CD1 9 + CD24
hi CD38 hi cells were markedly increased at 6 and 9 months following alemtuzumab treatment compared to pre-treatment level. By the end of the cycle (12 M), both the frequency and number were decreased, although did not reach pre-treatment level. The frequency and absolute number of CD19 + CD24 int CD38 int mature naïve B cells were increased at 6 and 9 months post-alemtuzumab, and at 12 months post-alemtuzumab, the frequency of CD19 + CD24 int CD38 int cells was lower than baseline level. A significant decrease in the frequency and absolute number of CD19 + CD24
hi CD38
− memory B cells was observed following alemtuzumab treatment ( Fig. 4a-c) .
The frequency and absolute number of CD1 9 + PD-L1 hi cells were increased at 6 and 9 months and maintained until the end of the cycle. The frequency of CD19 + PD-L1 int cells was significantly decreased at 6, 9, and 12 months following alemtuzumab. The absolute number of CD19 + PD-L1 int cells showed no significant difference. The frequency and absolute number of CD19 + PD-L1 low cells showed no significant difference (Fig. 5a-c) . 
Clinical implications
Among 11 patients treated with alemtuzumab, one patient experienced two severe relapses within 2 cycles of alemtuzumab infusion (Fig. 6a, b) . During his first attack, overshoot of total B cells was observed while the frequency of CD19
hi cells was remarkably decreased to 0.45% compared to previous follow-up ( 
Discussion
Little is known about the repopulating B cell pool following alemtuzumab. Cases of severely exacerbated central nervous system inflammation in alemtuzumab-treated MS patients have reported B-cell driven pathology, further emphasizing the importance of B cell study in alemtuzumab-treated patients [13] [14] [15] . We show that deficiency of CD19 +   CD24   hi   CD38 hi cells and CD19 + PD-L1 hi cells in the peripheral blood of relapsing MS patients are restored following alemtuzumab and that B cell distribution shifts towards naïve phenotype. In fact, the frequency of Bregs with disparate regulatory mechanisms exceeded baseline level, which may underlie the long-lasting suppression of disease activity.
Interestingly, both frequency and absolute number of CD19 + CD24 hi CD38 hi cells are reduced during and prior to relapse in an alemtuzumab-treated patient. CD1 9 + CD24 hi CD38 hi cells are known to maintain Tregs and limit the differentiation of T helper 1 (Th1) and T helper 17 (Th17) cells [16] . The deficiency of CD19 + C D24 hi CD38 hi cells could have a significant impact on the regulation of pathology. Indeed, recent studies have found that transitional B cells are impaired in various immune-related disorders [7, [16] [17] [18] , although conflicting results were observed in MS. [19, 20] In the early phase of alemtuzumab therapy, CD19 A recent study described that CD19 + PD-L1 hi cells are capable of suppressing Tfh cell differentiation and expansion through interaction with PD-1 on activated T cells [8] . Interaction causes an increase in signal transducer and activator of transcription 5 expression, a known suppressor of Tfh-cell development and expansion. Since Tfh cells aid germinal center formation and hence, involved in the formation of memory B cells and plasma cells, Tfh cells were thought to have pathogenic role in the B-cell-mediated autoimmune diseases. There has been several reports on Tfh cell involvement in MS. [22] [23] [24] [25] [21] . Due to vast composition of immature B cells and lack of understanding of their function, it remains to be further elucidated which specific immature B cell subset would be responsible for the secondary autoimmunity. Lastly, further functional study on the CD19 + CD24 hi CD38 hi cells would clarify the mechanism of action of alemtuzumab.
Conclusion
Our results highlight the preferential reconstitution of Bregs as a possible mechanism of action of alemtuzumab and CD19 + CD24 hi CD38 hi cells as a potential biomarker for disease activity. 
